Thursday , June 27 2019
Breaking News
Home / BUSINESS / Lupin’s Nagpur facility receives EIR from USFDA
Lupin’s Nagpur facility receives EIR from USFDA

Lupin’s Nagpur facility receives EIR from USFDA

Lupin has received the Establishment Inspection report (EIR) post the completion of a Pre-Approval Inspection (PAI) for its Phenytoin Sodium Extended Release 100 mg capsules, carried out by The United States Food and Drug Administration (USFDA) at its Nagpur facility in Maharashtra. The inspection conducted in September 2018 concluded without any observations.

Lupin’s Nagpur facility is the company’s latest site and manufactures Oral Solid Dosage products. The site also houses company’s state of the art injectable manufacturing facility.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Click & Download Udaipur Kiran App to read Latest News

Leave a Reply

Your email address will not be published. Required fields are marked *

*

Inline

Click & Download Udaipur Kiran App to read Latest News

Inline

Click & Download Udaipur Kiran App to read Latest News